NCT07797738Not yet recruiting
Prognostic Biomarkers for Patients With Human Papillomavirus (HPV) Positive Oropharyngeal Squamous Cell Carcinoma
Full Exchange Pharmacokinetic Model Analysis of Dynamic Contrast-Enhanced MRI Data for Identification of Vascular Habitats and Evaluation of Treatment Response in Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinomas
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
The purpose of this research study is to investigate the relationship between vascular habitats and treatment response AND to investigate the potential utility of dynamic contrast enhanced (DCE)-MRI derived parameters in predicting treatment response. This data can be used to assist in the development of a clinical decision support (CDS) tool for risk categorization and individualized decision-making. While "low-risk" patients could benefit from de-escalated radiation therapy, "high-risk" patients could receive early initiation of targeted therapies, or immunotherapies.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 20 Apr 2026
- Start date
- 15 Sept 2026
- Primary completion date
- 15 May 2028
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Head and neck cancer
- NCT number
- NCT07797738
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 15 Sept 2026 to the primary completion date, 15 May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of distant metastatic (M1) disease
- Implanted cardiac pacemaker or defibrillator, programmable shunts, deep brain stimulator, other implanted electronic devices which may be contraindicated for 3T MRI
- Presence of significant hemorrhage in and around the tumor bed that may potentially degrade the image quality
Other
- HPV- negative OPSCC
- Pregnancy
- Existence of significant co-morbidities at baseline which would prevent standard CRT treatment
- Significant claustrophobia.
Who the study is looking for
- Adult population (≥18 years) of both genders
- Biopsy confirmed diagnosis of OPSCC
- Known HPV status as determined by p16 immunohistochemistry (p16 positivity defined as \>70% of carcinoma cells showing nuclear reactivity) or polymerase chain reaction (PCR) sequencing
- Prior to any treatment except for incisional or excisional biopsies
- T0 to T4, N1 to N3, M0 (American Joint Committee on Cancer, 8th edition)
- A willingness to undergo multiple phlebotomy (blood withdrawal) during standard CRT for liquid biopsy analyses.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.